Vertex Pharmaceuticals

IRS: 043039129
VRTX
Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. The company's pipeline also includes genetic therapies like CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. In addition, Vertex is focusing on developing therapies for pain, type 1 diabetes, inflammatory diseases, influenza, and other rare diseases.

Founded
1989 (32 years)
Investor RelationsSEC
Revenue
6 billion (2020)

Want to see more? Sign up!